LPCN 8-K 2026-11-05

Lipocine Inc. (LPCN) 8-K dated 2026-11-05 — accession 0001493152-26-050098.

Lipocine Inc. (LPCN) is a biotechnology company listed on NASDAQ.

LPCN revenue $2.3M

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported LPCN revenue for 2025-12-31 was $2.0M. Net income was -$9.6M. Revenue was up 169.3% from 2023-12-31 to 2025-12-31. LPCN currently screens at market cap $19.3M.

Not investment advice. The LPCN SEC hub lists recent forms. The stock page is the research view.